Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

PubWeight™: 1.69‹?› | Rank: Top 3%

🔗 View Article (PMC 41126)

Published in Proc Natl Acad Sci U S A on August 29, 1995

Authors

K Uberla1, C Stahl-Hennig, D Böttiger, K Mätz-Rensing, F J Kaup, J Li, W A Haseltine, B Fleckenstein, G Hunsmann, B Oberg

Author Affiliations

1: Institute of Virology, University of Erlangen-Nürnberg, Germany.

Articles citing this

Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol (2003) 2.73

Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2009) 2.37

Why primate models matter. Am J Primatol (2014) 2.05

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79

Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol (2006) 1.76

A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76

Animal models for HIV/AIDS research. Nat Rev Microbiol (2012) 1.71

Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One (2008) 1.57

An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One (2011) 1.35

A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One (2009) 1.35

Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 1.30

Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol (2000) 1.28

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology (2007) 1.28

Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol (2000) 1.26

Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol (2005) 1.21

Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20

In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol (2004) 1.19

Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. J Virol (2000) 1.13

A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol (2002) 1.12

Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse. J Virol (2011) 1.11

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog (2010) 1.10

Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies. Curr Opin HIV AIDS (2013) 1.10

Nonhuman primate models of NeuroAIDS. J Neurovirol (2008) 1.07

The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol (2011) 1.07

Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother (2010) 1.05

Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 1.02

Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother (2003) 0.95

Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. PLoS One (2013) 0.92

Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques. PLoS One (2014) 0.92

Cyclophilin A-independent replication of a human immunodeficiency virus type 1 isolate carrying a small portion of the simian immunodeficiency virus SIV(MAC) gag capsid region. J Virol (2001) 0.92

Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines. J Virol (1998) 0.92

Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS One (2010) 0.83

Macaques as model hosts for studies of HIV-1 infection. Front Microbiol (2013) 0.83

Replication-competent chimeric lenti-oncovirus with expanded host cell tropism. J Virol (1997) 0.83

RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther (2009) 0.81

Animal Models for HIV Cure Research. Front Immunol (2016) 0.80

Breaking Barriers to an AIDS Model with Macaque-Tropic HIV-1 Derivatives. Biology (Basel) (2012) 0.80

Macaque-tropic human immunodeficiency virus type 1: breaking out of the host restriction factors. Front Microbiol (2013) 0.79

Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics. Antimicrob Agents Chemother (2014) 0.78

Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides. Virology (2006) 0.78

Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. Antimicrob Agents Chemother (2015) 0.77

Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution. PLoS One (2014) 0.77

Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART. PLoS One (2014) 0.77

Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success? J Int AIDS Soc (2015) 0.77

Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV. PLoS One (2014) 0.77

Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)). J Virol (2001) 0.76

Rectal pre-exposure prophylaxis (PrEP). Antiviral Res (2013) 0.75

Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. AIDS Res Ther (2016) 0.75

Articles cited by this

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 15.19

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63

Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69

Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27

The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 9.05

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76

A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30

Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science (1990) 8.07

Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (1988) 6.38

Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science (1985) 6.02

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (1990) 5.49

Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics (1985) 5.30

Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68

Infection of the SCID-hu mouse by HIV-1. Science (1988) 4.37

Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol (1988) 4.24

Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr (1992) 3.94

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother (1992) 3.11

Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol (1991) 3.05

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol (1992) 2.85

Human immunodeficiency virus infection of human-PBL-SCID mice. Science (1991) 2.77

Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science (1993) 1.97

HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses (1992) 1.90

Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr (1993) 1.58

Present status and future prospects for HIV therapies. Science (1993) 1.52

Effects of initiation of 3'-azido,3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis (1993) 1.35

HIV drug resistance. Annu Rev Pharmacol Toxicol (1993) 1.14

Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection. Virology (1992) 1.09

Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate. AIDS (1990) 1.07

Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr (1991) 1.04

Experimental infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus (SIVsm). J Acquir Immune Defic Syndr (1989) 1.01

A capture enzyme immunoassay for detection of HIV-2/SIV antigen. J Acquir Immune Defic Syndr (1991) 0.98

Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr (1991) 0.97

An animal model for antilentiviral therapy: effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Res Hum Retroviruses (1994) 0.96

Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3'-fluorothymidine. AIDS Res Hum Retroviruses (1992) 0.90

Articles by these authors

The sequence of the human genome. Science (2001) 101.55

The genome sequence of Drosophila melanogaster. Science (2000) 74.32

TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02

Comparative genomics of the eukaryotes. Science (2000) 26.62

Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast (1998) 23.00

A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell (1985) 16.46

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35

IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (1997) 11.89

The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28

Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet (1999) 11.10

The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell (1986) 10.76

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71

Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature (1986) 10.62

Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05

Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science (1984) 9.14

Mutation of a mutL homolog in hereditary colon cancer. Science (1994) 9.04

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89

Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23

Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85

Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76

Crystal structure of the RNA-binding domain of the U1 small nuclear ribonucleoprotein A. Nature (1990) 7.32

Rous sarcoma virus genome is terminally redundant: the 5' sequence. Proc Natl Acad Sci U S A (1977) 7.09

IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity (2001) 6.56

Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science (1985) 6.51

Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol (1996) 6.43

Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21

Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85

Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67

Sonic hedgehog signaling is essential for hair development. Curr Biol (1998) 5.58

Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol (1991) 5.49

Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 5.47

P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32

Primary structure of the herpesvirus saimiri genome. J Virol (1992) 5.26

Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature (1986) 5.24

Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science (1999) 5.22

Improvement of PCR amplified DNA sequencing with the aid of detergents. Nucleic Acids Res (1990) 5.13

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01

Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature (1984) 4.90

Ordered transcription of RNA tumor virus genomes. J Mol Biol (1976) 4.78

Integration of human immunodeficiency virus type 1 DNA in vitro. Proc Natl Acad Sci U S A (1990) 4.75

Crystal structures of two Sm protein complexes and their implications for the assembly of the spliceosomal snRNPs. Cell (1999) 4.57

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53

Effects of mutations within the 3' orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity. J Virol (1986) 4.48

Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr (1990) 4.35

Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35

Connexins regulate calcium signaling by controlling ATP release. Proc Natl Acad Sci U S A (1998) 4.35

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res (1997) 4.32

Tissue-specific transcription preference as a determinant of cell tropism and leukaemogenic potential of murine retroviruses. Nature (1984) 4.30

Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1994) 4.28

Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3. EMBO J (2001) 4.23

Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol (1993) 4.22

A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell (1998) 4.21

Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother (2011) 4.21

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21

Dominance is the major genetic basis of heterosis in rice as revealed by QTL analysis using molecular markers. Genetics (1995) 4.18

Identification of a protein encoded by the vpu gene of HIV-1. Nature (1988) 4.05

Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science (1997) 4.03

Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest (1997) 4.00

Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol (2003) 3.93

MSI and MSII made on ribosome in idling step of protein synthesis. Nature (1972) 3.89

Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol (1997) 3.88

Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85

Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology (1998) 3.79

Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature (1987) 3.77

Brassinosteroid-insensitive-1 is a ubiquitously expressed leucine-rich repeat receptor serine/threonine kinase. Plant Physiol (2000) 3.73

UV-induced mutation hotspots occur at DNA damage hotspots. Nature (1982) 3.63

Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A (1993) 3.63

Conformation and function of the N-linked glycan in the adhesion domain of human CD2. Science (1995) 3.62

Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem (2001) 3.60

Light control of Arabidopsis development entails coordinated regulation of genome expression and cellular pathways. Plant Cell (2001) 3.60

Structural and functional characterization of human immunodeficiency virus tat protein. J Virol (1989) 3.57

Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55

Synthesis of guanosine tetra- and pentaphosphate requires the presence of a codon-specific, uncharged transfer ribonucleic acid in the acceptor site of ribosomes. Proc Natl Acad Sci U S A (1973) 3.52

Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44

Sequence specific cleavage of DNA by the antitumor antibiotics neocarzinostatin and bleomycin. Proc Natl Acad Sci U S A (1978) 3.43

Nucleotide sequence of the envelope gene of Friend murine leukemia virus. J Virol (1983) 3.41

Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37

LifeLines: using visualization to enhance navigation and analysis of patient records. Proc AMIA Symp (1998) 3.35

Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther (2014) 3.32

Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27

Methylation of Herpesvirus saimiri DNA in lymphoid tumor cell lines. Proc Natl Acad Sci U S A (1979) 3.24

Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin. Neuron (2001) 3.20

Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20

Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol (1987) 3.18

Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17

Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol (1984) 3.15

Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly. N Engl J Med (1998) 3.13

Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem (2001) 3.13

The family Herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol (1992) 3.09

Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol (1991) 3.09

Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychol Med (2010) 3.08

Perception of brassinosteroids by the extracellular domain of the receptor kinase BRI1. Science (2000) 3.07

Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 3.03

Coping skills training for youth with diabetes mellitus has long-lasting effects on metabolic control and quality of life. J Pediatr (2000) 3.02

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00

The Arabidopsis deetiolated2 mutant is blocked early in brassinosteroid biosynthesis. Plant Cell (1997) 3.00